Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

Prior to Pfizer's acquisition of the company, Biohaven knowingly caused the submission of false claims to Medicare and other federal healthcare programs by paying providers to induce them to write ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Nurtec ODT, also known as Rimegepant, was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021.

The settlement resolves allegations that Biohaven paid improper remuneration, including speaker honoraria and high-end restaurant meals, to physicians and other healthcare professionals to promote ...

These activities violate the Anti-Kickback Statute. Nurtec ODT (rimegepant) (CPSC) Some providers were allegedly paid tens of thousands of dollars, sometimes exceeding $100,000, for these programs.

Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce prescriptions for its migraine drug Nurtec ODT. Read more here.

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement ...